Targets › SLC22A8
4 programs from 4 companies in 5 trials: 3 Phase 2, 1 Phase 3, 1 Phase 1; Neurology, Oncology, Psychiatry; next expected readout Dec 2026.
Functions as an organic anion/dicarboxylate exchanger that couples organic anion uptake indirectly to the sodium gradient. Transports organic anions such as estrone 3-sulfate (E1S) and urate in exchange for dicarboxylates such as glutarate or ketoglutarate (2-oxoglutarate). (UniProt, Q8TCC7)
Open in Phaseline: the race on SLC22A8, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Miami | Probenecid Solute carrier family 22 member 6 inhibitor; Solute carrier family 22 member 8 inhibitor; Solute carrier family 22 member 11 inhibitor | SLC22A6, SLC22A8, SLC22A11 | Phase 3 | Infertility, Male | May 2027 |
| Memorial Sloan Kettering Cancer Center | Busulfan Alkylating agent; DNA cross-linking agent | SLC22A8 | Phase 2 | AML; Hematologic Malignancies | Dec 2026 |
| Fondation Ophtalmologique Adolphe de Rothschild | Probenecid Solute carrier family 22 member 6 inhibitor; Solute carrier family 22 member 8 inhibitor; Solute carrier family 22 member 11 inhibitor | SLC22A6, SLC22A8, SLC22A11 | Phase 2 | Focal Epilepsy | Sep 2029 |
| Brown University | Probenecid Solute carrier family 22 member 6 inhibitor; Solute carrier family 22 member 8 inhibitor; Solute carrier family 22 member 11 inhibitor | SLC22A6, SLC22A8, SLC22A11 | Phase 2 | Alcohol Use Disorder (AUD) | Dec 2030 |
Infertility, Male (1) AML (1) Hematologic Malignancies (1) Alcohol Use Disorder (AUD) (1) Focal Epilepsy (1)
small molecule (4)
University of Miami (1) Memorial Sloan Kettering Cancer Center (1) Brown University (1) Fondation Ophtalmologique Adolphe de Rothschild (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.